Evergreen or deciduous? Australian trends in relation to the 'evergreening' of patents

Simple item page
dc.contributor.authorChalmers, Robert Andrewen
dc.contributor.schoolLaw Schoolen
dc.date.issued2006en
dc.description.abstractThe so-called ‘evergreening’ of pharmaceutical patents has become an issue of major public concern in the wake of the Australia–United States Free Trade Agreement and the amendments it requires to the Therapeutics Goods Act 1989 (Cth). The effect of these amendments was to place additional obligations on manufacturers of generic (unpatented) pharmaceuticals. Some additional provisions were also included in an attempt to safeguard against potentially ‘illegitimate’ patent infringement action taken by patentees against such manufacturers. This article examines these provisions and their likely effect on the patent protection strategies adopted by the pharmaceutical industry. It also considers recent responses to these strategies by the patents administration system and the courts — in particular, the decision of Arrow Pharmaceuticals Ltd v Merck & Co Inc.en
dc.description.statementofresponsibilityRobert Chalmersen
dc.identifier.citationMelbourne University Law Review, 2006; 30(1):29-61en
dc.identifier.issn0025-8938en
dc.identifier.urihttp://hdl.handle.net/2440/35386
dc.language.isoenen
dc.publisherMelbourne University Law Reviewen
dc.rightsCopyright (c) 2006 Melbourne University Law Review Association, Inc.en
dc.source.urihttp://mulr.law.unimelb.edu.au/go/issues/previous-issues/-2006-volume-30/-2006-volume-30-1en
dc.titleEvergreen or deciduous? Australian trends in relation to the 'evergreening' of patentsen
dc.typeJournal articleen

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_35386.pdf
Size:
349.95 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Law publications